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Originally discovered as regulators of developmental timing in C. elegans, microRNAs
(miRNAs) have emerged as modulators of nearly every cellular process, from normal
development to pathogenesis. With the advent of whole genome libraries of miRNA
mimics suitable for high throughput screening, it is possible to comprehensively evaluate
the function of each member of the miRNAome in cell-based assays. Since the relatively
few microRNAs in the genome are thought to directly regulate a large portion of the
proteome, miRNAome screening, coupledwith the identification of the regulated proteins,
might be a powerful new approach to gaining insight into complex biological processes.
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INTRODUCTION
Transcriptomics, proteomics and other ‘omics data describing
biological phenomena are amassing at an astounding rate that
was unimaginable even a few years ago. In principle, researchers
will be able to utilize these data to formulate and answer
complex biological questions—including important questions in
cardiovascular medicine. The amount of primary data is grow-
ing exponentially with the availability of disease-specific assays
and powerful new technologies, such as Next-Gen Sequencing
(NGS aka RNA-Seq) (Marioni et al., 2008; Wang et al., 2009),
ChiP-SEQ (Johnson et al., 2007), protein microarrays (Melton,
2004; Mattoon and Schweitzer, 2009), and mass-spectroscopy-
based proteomics (Hernandez et al., 2006). As of November
2012, the Gene Expression Omnibus (http://www.ncbi.nlm.nih.
gov/geo/) lists 2720 datasets covering over 800,000 assays while
ArrayExpress at European Bioinformatics Institute contains data
from 33,868 datasets covering nearly a million assays (http://
www.ebi.ac.uk/arrayexpress/). Moreover, advances in computa-
tional algorithms to identify putative connections among nodes
have magnified the effect, making the sum total of ‘omics infor-
mation seemingly intractable. For example, the Human Protein
Reference Database (http://www.hprd.org) (Keshava Prasad et al.,
2009) contains information on a daunting 41,327 protein-protein
interactions (PPIs), and this is probably a lower estimate. Making
sense of the primary and derived information is arguably one of
the largest challenges in systems biology.
One approach is to use high throughput biological screening
technology to probe the nodes and networks, providing exper-
imental validation of the computationally determined networks.
Nearly five decades ago, the pharmaceutical industry refocused its
efforts on screening and has since developed advanced technol-
ogy, expertise, and chemical libraries, accelerating the production
of new drugs that have had an enormous impact on longevity
and quality of life (Kaye and Krum, 2007). A recent byproduct
of this activity has been the adoption of high throughput screen-
ing approaches in academia. Although the original screening
applications were target-centric, essentially designed to discover
molecules that interact with a known target, the last decade has
seen the development of assays designed to explore complex bio-
logical mechanisms including assays based on human induced
pluripotent stem cells (hiPSCs) to model cardiovascular disease
(Nsair and MacLellan, 2011; Mercola et al., 2013). Such assays
are typically phenotypic, meaning that they read out morphol-
ogy, behavior or physiology of cells in culture or even in whole
organisms such as zebrafish or Drosophila. The advantage of phe-
notypic screening as a discovery tool is that it probes a plethora of
biomolecules involved in a given phenotype. Phenotypic screen-
ing coupled to the identification of cellular proteins or genes
targeted in the screens is termed “chemical” or “functional”
genomics, depending on whether the library is a chemical or
a nucleic acid, respectively, by analogy to the unbiased evalua-
tion of the genome by classical “forward” genetic screening by
mutagenesis (Stockwell, 2000).
In this review, we discuss functional genomics technologies for
identifying cellular proteins and genes of interest, and applica-
tion of these approaches to sift through and validate the vastness
of information to gain meaningful insight into mechanisms of
complex phenotypes and diseases. Key among the technologies
is RNA interference (siRNA or shRNA) technology, which has
proven to be a powerful method to evaluate the function of can-
didate genes, and even screen entire genomes to reveal pathway
components that govern complex processes, including stem cell
identity (Chia et al., 2010) and sensitization of tumor cells to
chemotherapeutics (Whitehurst et al., 2007). By probing all genes,
whole-genome RNAi strategies offers a comprehensive alternative
to chemical screening to interrogate the vastness of the proteome,
estimated at over 1,000,000 total human proteins, including splice
variants, post-translational modifications and somatic mutations
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(Jensen, 2004). This number greatly overshadows the calculated
3000–10,0000 so-called “druggable” proteins, that have topologi-
cally defined drug-binding pockets that are considered desirable,
which includes enzymes, GPCRs, kinases, nuclear receptors and
ion channels (Overington et al., 2006). Targeting only these
classes, however, ignores many biologically interesting proteins
that play important roles in disease, such as transcription factors
and scaffold proteins (Stockwell, 2000; Crews, 2010).
In addition to unbiased siRNA or shRNA screens, we explore
the concept that miRNA screening might be a particularly
promisingmeans of identifying critical proteins in biological con-
trol networks. miRNAs are endogenous, ∼22-nucleotide single-
stranded RNAs that selectively bind and suppressmultiple mRNA
targets in the context of the RNA-Induced Silencing Complex
(miRISC). There are only about 2000 known miRNAs in the
human genome (http://www.mirbase.org), yet they are estimated
to regulate 60% of the total proteome (Friedman et al., 2009).
By governing translation and mRNA stability, miRNAs fine-
tune nearly every normal and pathological process examined
(Filipowicz et al., 2008; Bartel, 2009). In cardiovascular biology,
miRNAs control early embryonic development and adult disease,
exemplified by the essential roles of miR-1 and miR-133 in heart
development (Zhao et al., 2007; Liu et al., 2008) and miR-21 and
miR-208a in cardiac remodeling after myocardial infarction (Van
Rooij et al., 2007; Thum et al., 2008) and metabolism (Grueter
et al., 2012). Given their evolutionarily conserved, and arguably
optimized, role in regulating proteins that occupy critical nodes
in networks controlling complex biology (Shreenivasaiah et al.,
2010), we postulate that screening with miRNA libraries could
be used to elucidate disease-modifying mechanisms (Figure 1).
At least conceptually, the outcome of a miRNA screen can be
informative regardless of whether or not a particular miRNA is
normally involved in the process being probed. On the one hand
these screens may identify miRNAs that normally modulate bio-
logical phenomena, adding new dimensions to the miRNAome.
On the other hand, miRNAs, when ectopically expressed, will
downregulate proteins they do not normally regulate in a native
biological context. Thus, miRNA screening, like chemical library
screening, can reveal key regulatory proteins that elicit a given
phenotype. One major roadblock is the limited ability to identify
high confidence targets of miRNAs. If emerging technologies can
overcome this issue, miRNA screening might become a tremen-
dously powerful approach to elucidating systems-level control
networks and identifying critical node proteins that might be ide-
ally poised as drug targets. In this review we discuss the current
technologies for functional miRNA screening and target identifi-
cation, and consider the challenges that must be resolved in order
to achieve the potential offered by the approach.
FUNCTIONAL GENOMICS TECHNOLOGY
Oligonucleotide libraries offer an alternative to chemical libraries
for probing cardiovascular or other disease phenotypes. RNA
interference (siRNA or shRNA) technology functions by intro-
ducing a double stranded small interfering (siRNA) or short
hairpin (shRNA) RNA into the cell that basepairs with cognate
mRNAs in the RNA-induced Silencing Complex (RISC), targeting
the mRNAs for degradation.
Advances in oligonucleotide chemistry have improved siRNA
technologies. For instance, modifying the second position of siR-
NAs with 2’-O-methyl linkage significantly reduces off-target
effects that result when siRNAs act like miRNAs (i.e. tar-
get imprecisely base-paired mRNAs for downregulation by the
RISC) (Jackson et al., 2006). Other chemical or sequence mod-
ifications made to the ends of the oligonucleotide strands
dictate which strand of the oligonucleotide duplex become
packaged into RISC, reducing off-target effects caused by the
complementary strand (Schwarz et al., 2003). Furthermore,
it has become common to screen pools of multiple siRNAs
against a single mRNA target to increase the likelihood of
eliciting a phenotypic effect (Parsons et al., 2009). Modern
commercial siRNA libraries use these technologies to pro-
vide specific and potent knockdown of target genes. Examples
of genome-wide siRNA screening libraries include Stealth
RNAi™ and Silencer Select (Life Technologies), ON-TARGETplus
and siGENOME (ThermoScientific), AccuTarget (Bioneer), and
MISSION® siRNA (Sigma-Aldrich).
Compared to standard siRNAs, short hairpin RNA (shRNA)
offers multiple advantages. This technology uses lessons learned
from miRNA research, harnessing the cell’s miRNA biogenesis
machinery to process the hairpin into specific siRNA duplexes.
FIGURE 1 | Moderate throughput screening of miRNAs in cell-based
assays. Cells are transfected with individual miRNAs from a miRNAome
library in 384-well or other multiwell format (1). Following culture, either
image-based (shown) or plate-reader acquisition of data, and subsequent
analysis (2), profiles miRNAs by activity shown in a volcano plot (3), providing
a dataset for network analysis (4) and Figure 2.
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And, unlike many miRNAs, the shRNA sequences are typi-
cally optimized to ensure only one strand becomes packaged
into RISC. shRNA is most commonly delivered to cells by
transfection or infection using plasmid or viral vectors capa-
ble of providing long-lasting downregulation of target genes.
The first shRNA libraries used RNA Polymerase III to transcribe
the hairpin sequence (Berns et al., 2004; Moffat et al., 2006).
Subsequent studies, however, showed that design based on pri-
mary miRNA transcripts (pri-miRNA) gave improved efficiency
of siRNA packaging into RISC (Chang et al., 2006). Additionally,
primary miRNA transcript-based shRNAs are expressed via RNA
Polymerase II, allowing co-expression of fluorescent or drug-
selectable transgene markers from a single promoter. Another
powerful advance in shRNA technology is the use of pooled
barcoded shRNAs combined with high throughput sequencing
deconvolution, circumventing the need for multi-well plates, liq-
uid handling robots, and large amounts of reagents (Sims et al.,
2011). A variety of libraries are available commercially, each
utilizing slightly different design strategies and delivery vectors.
Examples include MISSION® (Sigma-Aldrich), BLOCK-iT™
(Life Technologies) DECIPHER (Cellecta – Free to academia),
and Decode Pooled Lentiviral shRNAs (Thermo Scientific).
LOGIC OF miRNAs AS SCREENING TOOLS
miRNAs make an intriguing starting point for phenotypic screen-
ing, as they have many desirable qualities that may allow identifi-
cation of pathways or networks involved in a particular process
that might not be found using single gene screening methods.
miRNAs co-evolved to regulate expression of the transcriptome
and proteome, and therefore have selective relationships with
their targets and the processes they regulate. Indeed, it is thought
that entire genomes have adjusted to the pool of miRNAs in each
organism by selectively removing potential target sites that, if
present in transcripts, would cause undesirable downregulation
that would be detrimental to the organism (Stark et al., 2005).
Perhaps the most useful aspect of miRNA-genome co-evolution
is that each miRNA typically targets numerous genes. Varying
estimates have been suggested using computational target pre-
dictions as guidelines, but most telling is that expression profiles
after miRNA overexpression or removal indicates that a large
portion of the transcriptome/proteome is under the control of
miRNAs, with each miRNA potentially regulating on the order
of hundreds of proteins (Filipowicz et al., 2008; Selbach et al.,
2008; Bartel, 2009; Friedman et al., 2009; Shirdel et al., 2011).
For instance, miR-223 is estimated by proteomics to affect the
expression of more than 200 genes in neutrophils alone (Baek
et al., 2008). On the other hand, deletion of certain miRNAs cause
no discernible developmental phenotypes (Miska et al., 2007;
Alvarez-Saavedra and Horvitz, 2010), indicating that they affect
only a small number of targets which are relatively specialized
or that their effect on their targets is only a small percentage of
the total expression level. These miRNAs, especially those that
are evolutionary ‘newborns’ (i.e. found only in one species or
genus), may function mainly to buffer expression of their tar-
gets against fluctuation due to intrinsic and extrinsic factors, and
have for this reason been termed “canalizing” miRNAs (Wu et al.,
2009).
From a systems biology and drug target identification perspec-
tive, the most remarkable feature of miRNAs is that they often
target proteins at the nodes of important regulatory pathways
(Shreenivasaiah et al., 2010; Ichimura et al., 2011). Moreover,
many miRNAs, especially those conserved within vertebrates,
govern multiple proteins within a single pathway (Cui et al.,
2006; Ichimura et al., 2011; Sass et al., 2011; Shirdel et al., 2011).
Consequently, these miRNAs function as physiological or devel-
opmental switches that fine-tune the proteome of a given cell
or tissue. Specific cases include the regulation of Wnt signal-
ing components by miR-34 (Kim et al., 2011), regulation of
alternative splicing by miR-23 (Kalsotra et al., 2010), regulation
of the p53 network by miR-125b (Le et al., 2011), regulation
of phosphatidylinositol- 3-OH kinase (PI(3)K)–AKT signaling
(Small et al., 2010), and suppression of smooth muscle specific
proteins in cardiomyocytes (Liu et al., 2008). miR-21 targets
PPAR alpha pathway in modulating flow-induced endothelial
inflammation (Zhou et al., 2011) and miR-23b is involved in
endothelial cell growth (Wang et al., 2010).
Since miRNAs govern such large-scale changes in translation,
it is perhaps not surprising that they have been found to be
involved in nearly every normal and pathological process exam-
ined so far (Filipowicz et al., 2008; Bartel, 2009). Given the
evolutionarily strategic position of miRNAs and their ability to
directly control expression of a large portion of the proteome
through simultaneous targeting of multiple genes, they poten-
tially offer an efficient means to interrogate critical processes and
the potential to identify genes of interest for phenotypes which
may not be affected by the single gene mutation or knockdown
approaches typical of most classical genetic or even chemical
biology and si/shRNA screening methods. As an example, recent
whole genome miRNA screens have led to the discovery of miR-
NAs and target genes that allocate mesoderm and ectoderm as
distinct from endoderm in the early embryo (Colas et al., 2012),
modulate cardiomyocyte hypertrophy (Jentzsch et al., 2012), and
regulate cell cycle re-entry of adult cardiomyocytes (Eulalio et al.,
2012).
Cancer is another area where microRNA screening might
reveal unanticipated therapeutic targets. For instance, recent
whole-genome miRNA screen identified miR-16, miR-96, miR-
182, and miR-497 as potent inhibitors of melanoma cell prolif-
eration and viability (Poell et al., 2012), suggesting that mimics
of these miRNAs optimized for use in human patients could be
important therapeutic molecules. In addition to understanding
the transformed state, an important aspect of cancer research
where miRNA screening could be useful might be in deciphering
the cellular pathways and proteins that mediate drug resistance,
which could suggest combinatorial drug action, such as been
recently addressed through proteomics (Erler and Linding, 2012).
We expect that, in the near future, miRNA screens will discover
many phenotype-modifying genes that would not and have not
been identified through siRNA and chemical screens, as well as
identify numerous miRNAs whose involvement in disease phe-
notype, progression or drug-responsiveness will provide new
therapeutic targets.
Many libraries are available commercially that allow screen-
ing using miRNA mimics either in hairpin or duplex format for
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the majority of known miRNAs of variety of model organisms.
The oligonucleotide mimics are typically chemically modified
in a manner similar to the siRNA products described above
so that one strand is preferentially packaged into the RISC.
Examples include Ambion® Pre-miR Precursors and miRvana™
miRNAmimics (Life Technologies), MISSION®(Sigma-Aldrich),
miRIDIAN (Thermo Scientific). Unlike siRNA/shRNA screen-
ing, in which the gene affecting the phenotype is known a priori
(although the mRNA target must be confirmed) the degeneracy
of miRNA:mRNA interactions means that screening campaigns
must include steps to identify the mRNA target(s) responsible for
the phenotype. Below we discuss computational and biochemi-
cal methods currently used for target identification, their efficacy,
and possible ways to improve the pipeline from screen dataset to
target knowledge (Figure 2).
COMPUTATIONAL APPROACHES TO TARGET
IDENTIFICATION
The development of computational tools for miRNA target
prediction began in the early 2000’s shortly after the discov-
ery that miRNAs are pervasive members of animal genomes
(Lagos-Quintana et al., 2001). Currently, many different tools
are available, most utilizing a common set of concepts to inform
their prediction algorithms, such as seed-match (complementar-
ity between the 5′ of the miRNA—typically bases 2–8—and the
bases in 3′ untranslated region (3′UTR) of an mRNA), evolution-
ary conservation of target sites and thermodynamic (free-energy)
considerations for the interaction [Table1; for in depth reviews
see (Alexiou et al., 2009; Xia et al., 2009; Witkos et al., 2011)].
The initial algorithms turned out to provide high sensitivity
but low specificity (high rate of false-positives). One approach
FIGURE 2 | Computational and experimental strategies to identify
miRNA targets. miRNAs target multiple proteins, and in certain instances
a single family of miRNAs target multiple proteins involved in a common
biological process, through imprecise basepairing with recognition
sequences in mRNA (see text). Commonly used computational and
biochemical approaches to identify targets are summarized along with
focused strategies for confirming direct interaction of a miRNA with
particular mRNA targets.
to solve this problem has been to prioritize targets predicted
by multiple algorithms; however, taking the intersection (rather
than union) leads to a corresponding loss of sensitivity (Alexiou
et al., 2009). Developing advanced algorithms to take contex-
tual cues into account would be a major advance. Some new
algorithms strive to incorporate more comprehensive feature
sets from experimental data and/or machine learning to try to
improve the ratio of sensitivity to specificity. An improved ver-
sion of TargetScan (Lewis et al., 2005), called TargetScanS, uses 6
instead of 7 nucleotide seed match followed by an A-anchor and
incorporates information on the surrounding mRNA sequence
to compute a context score which models the relative contri-
butions of previously identified targeting features, including site
type, site number, site location, local A+U content and 3′-
supplementary pairing (Grimson et al., 2007; Garcia et al., 2011).
An improved context-score called context+ score also consid-
ers target-site abundance and seed-pairing stability (Garcia et al.,
2011). A multiple linear regression model was trained using 11
microarray data sets, and the context+ scores performed bet-
ter than previous models. miRTarget2 is an improvement of the
original miRTarget algorithm and uses a support-vector machine
learning (SVM) algorithm to build prediction models based on
a set of 131 features including seed conservation, other seed
types, base composition, and secondary structure (Wang and
El Naqa, 2008). SVMicrO is an SVM-based recent algorithm
for miRNA target prediction in animals which tries to improve
both sensitivity and specificity of prediction by using positive
and negative target data for training the classifier (Liu et al.,
2010). The algorithm increases sensitivity by only requiring a
5 basepair seed-match, and is trained using about 1000 posi-
tive miRNA-target pairs and microarray data-based 3500 negative
miRNA-target pairs. The authors have shown a better true posi-
tive rate for SVMicrO as compared to many other popular algo-
rithms on both the training data as well as a separate proteomic
test data.
BIOCHEMICAL AND PROTEOMIC APPROACHES TO TARGET
IDENTIFICATION
Despite these advances, computational prediction of miRNA tar-
get sites in mammals are generally considered too error-prone
to be used as the sole means of target identification, reviewed
in Alexiou et al. (2009). We ascribe the problem to the fact that
miRNA-mRNA pairing “rules” of most computational prediction
algorithms were determined based on a small number of known
targets discovered through genetic mutations and by observing
changes in target regulation after abrogation of the interaction by
site-directed mutation of the recognition sequence. As discussed
above, contextual cues that influence site accessibility include
sequences surrounding the recognition site and RNA-binding
cofactors present in the cell. It is too soon to tell whether the inno-
vations in algorithm design described in the preceding section will
remedy this situation, but given that they are unlikely to model
the influences of the cellular context, we expect that the problem
of false positives and negatives will remain a serious issue. Thus,
while many true targets have been discovered using various target
prediction algorithms, they probably comprise a small percentage
of the total regulatory network of the miRNA pathway.
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Table 1 | Commonly used computational tools and algorithms for identification of miRNA targets.
Software/tools Evolutionary
conservation
Base-pairing/seed-
match
criteria
Surrounding
sequence
Energy
consideration
Additional
filters/rules/learning
using microarray
data
TargetScan Across vertebrates:
human, mouse and
rat
7-nt (W-C
complementarity for
bases 2-8 of miRNA)
Seed-match extended
on both sides
Yes, z-score to energy
of miR-target
interaction
No
TargetScanS Similar; dog and
chicken as well
6-nt and A-anchor
G-W wobble pair
allowed
Yes Yes Latest version can use
context information.
miRanda D. melanogaster, D.
pseudoobscura and
A. gambiae; now
extended to mouse,
human and fish
7-nt and weighted
seed-match
Yes No
Diana-microT 5- to 7-nt, conditional
G-W wobble pair and
bulge allowed
Uses a 38-nt sliding
window
Yes, uses as a filter to
find miRNA3′-UTR
pairs
Specialized for target
mRNAs with single
miRNA recognition
element
PicTar vertebrates, flies and
nematodes
7-nt Yes Finds common targets
of several miRNAs
using combinations of
transcription factor
binding sites.
miRTarget,
miRTarget2 and
miRDB
Yes 7-nt Yes, duplex stability Uses microarray data
for positive and
negative targets. SVM
is used in miRTarget2
to incorporate features
such as other seed
types, base
composition, and
secondary structure.
SVMicrO Yes 5-nt to increase
sensitivity
Yes Yes Similar to miRTaget2.
Bayesian approach is
also used.
Abbreviation: W-C, Watson-Crick; SVM, support-vector machine.
TRANSCRIPTOMICS AND PROTEOMICS TECHNIQUES
The first attempt at biochemically boot-strapping the identifi-
cation of miRNA targets at a transcriptome scale assayed the
total change in mRNA expression profile by microarray analy-
sis caused by transfection of single miRNAs into human cells
(Lim et al., 2005). In this case, transfection of either miR-1
or miR-124 shifted mRNA expression such that there was a
greater resemblance to the natural profile of seen muscle or
brain, the organs that normally express these miRNAs during
development. Subsequent microarray studies looked at global
changes in mRNA expression resulting from single miRNA over-
expression, depletion, genetic mutants, and depletion of all
miRNAs through mutations in the miRNA biogenesis pathway
(Giraldez et al., 2006; Linsley et al., 2007). These early analyses
proved that microarray profiling can provide a first approxi-
mation of the genes regulated by single or multiple miRNAs,
consistent with the observation that the majority of changes
in protein levels induced by miRNA regulation are attributable
to changes in mRNA expression (Guo et al., 2010). However,
as with microarray transcriptome analysis of transcription fac-
tor mutants, these analyses alone cannot reveal whether genes
are the direct targets of the miRNAs, or are affected indi-
rectly by factors downstream of the primary effector molecules.
Although upregulated genes are unlikely to be directly affected
by miRNA activity and can be excluded as direct targets, down-
regulated genes must be analyzed in greater detail to determine
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whether or not they are targeted directly by the miRNA(s) in
question.
The simple comparison of downregulated transcript sets with
the computationally predicted mRNA target sets has yielded
poor correlations (Alexiou et al., 2009). While sequences of
downregulated mRNAs are often enriched for “seed” comple-
mentary sequences, this is not always observed. For instance,
downregulated genes lacking “seed” matches may be secon-
darily affected by changes in direct target genes, but they
can also be direct targets which harbor less common types
of miRNA target sites, such as 3′ compensatory (Brennecke
et al., 2005) centered sites (Shin et al., 2010), or other non-
canonical binding structures (Helwak et al., 2013). Whether
a transcript is a direct target of a particular miRNA may
or may not be relevant to the goals of an individual screen
experiment. However, if this knowledge is required, subsequent
experiments will be needed to confirm a direct miRNA:mRNA
interaction. Typically, confirmation is based on abolishing reg-
ulation by mutation of the miRNA recognition site within the
mRNA, and an alternative is to mask the binding site with a
complementary oligoribonucleotide, preventing miRNA bind-
ing and mRNA degradation (for example, see Colas et al.,
2012).
Quantitative proteomics is an analogous target discovery strat-
egy that has gained traction in recent years, as it provides a
direct readout of the ultimate effect of miRNA activity (Vinther
et al., 2006; Baek et al., 2008; Yang et al., 2009, 2010; Chen
et al., 2011; Yan et al., 2011). This method provides an advantage
over microarray analysis, since it can detect changes in expres-
sion levels of a protein even when its cognate mRNA is not
downregulated at an appreciable level. Early instances include
an analysis of miR-1 in HeLa cells (Vinther et al., 2006), an
analysis of miR-1, 124, and 181 in HeLa cells and miR-223
in mouse knockout neutrophils (Baek et al., 2008), and subse-
quent studies have examined miR-21 and miR-143 (Yang et al.,
2009, 2010). An example of an advanced proteomics analysis
is a recent study that used Stable Isotope Labeling by Amino
acids in Cell culture (SILAC) to detect differences in protein
expression induced by the overexpression of miR-34a and miR-
29 (Bargaje et al., 2012). Although a number of proteins related
to the biological function of the miRNAs in apoptosis were
found to change, the study discusses several limitations. Chief
among these is that miRNAs often only reduce target protein
levels by 30–60% (Hendrickson et al., 2009) meaning that com-
monly applied thresholds (e.g., 2-fold) are inappropriate and a
more robust statistical analysis is needed. In addition, variation
in protein stability might require analyses at multiple timepoints.
Finally, only about 10% of the proteins detected as downregu-
lated by Bargaje et al. for miR-34a andmiR-29 were also predicted
by the consensus of 5 computational algorithms (Bargaje et al.,
2012), highlighting the need for evaluating potential indirect
effects (in addition to validating potential targets). Finally, as for
microarray analyses, many interesting targets might be missed
due to low abundance. Nevertheless, even at current depths, the
recent studies suggest that proteomics analysis can yield a num-
ber of targets that could feed a validation and systems analysis
pipeline.
IMMUNOPRECIPITATION-BASED TARGET IDENTIFICATION
TECHNIQUES
Biochemistry-based experiments have been developed to directly
identify the target sequences bound by miRNAs. The first
attempts of this type of assay immunoprecipitated the RISC com-
ponents, and then performed microarrays or RNA sequencing
to identify the captured mRNAs (Beitzinger et al., 2007; Easow
et al., 2007; Zhang et al., 2007; Hendrickson et al., 2008). Such
methods are promising since they should be able to identify
the direct targets of mRNAs. A number of procedural modifica-
tions have improved the initial process to reduce false positive
rates and increase the depth and specificity of targets discov-
ered. These methods, referred to as Argonaute CLIP-Seq (Zisoulis
et al., 2010) or Argonaute HITS-CLIP (Chi et al., 2009), utilize
cross-linking prior to immunoprecipitation to firmly associate
target mRNAs with miRISC. After immunoprecipitation, exposed
RNA ends not covered by RISC protein are enzymatically cleaved
before linkers are ligated to the bound RNA and then processed
using deep sequencing. After sequencing, high tag count segments
are deemed to be bonafide miRNA target sites, which are then
matched computationally to individual transcripts.
Analysis of the putative recognition sites discovered by these
methods indicated that not every enriched sequence has a good
“seed” match to known miRNAs. This may be in part due to
unknown miRNAs being present in the genome, but recent mass
sequencing efforts suggest that the vast majority of miRNAs
have been discovered in the major model organisms. The most
likely explanation, therefore, is that the contextual cues and non-
canonical pairing indeed play important roles in determining
miRNA-mRNA recognition, and the data from these experiments
are helping to re-define the miRNA-mRNA binding rules (Elefant
et al., 2011; Wen et al., 2011).
Additional refinements to the immunoprecipitation approach
have improved specificity and sensitivity. PAR-CLIP (Hafner
et al., 2010) and miR-TRAP (Baigude et al., 2012) both include
photoactivatable ribonucleosides in transfected miRNA mimics
to allow specific cross-linking sites and higher wavelength cross-
linking, which is less harmful to cells and improves RNA recovery.
The PAR-CLIP method has been used to achieve single nucleotide
resolution of the binding site due to the specificity of the cross-
linking. Modifications to denaturing conditions and the nuclease
digestion of extraneous RNA can improve data by reducing biases
resulting from conditions used in previous methods (Kishore
et al., 2011).
These approaches often rely on overexpression of a particular
miRNA to load the RISC. The over-representation of a specific
miRNA in active RISC can cause off-target interactions, pos-
sibly influenced by dosage and elevated contribution of seed
sequence similarity to miRNA:mRNA association (Birmingham
et al., 2006; Arvey et al., 2010). This phenomenon, however,
might recapitulate the function of the overexpressed miRNA in
the screen assay itself, and thus may be relevant to the identifi-
cation of targets. Conversely, endogenous miRNA programmed
RISC will always comprise some percentage of the total data.
Both errors will introduce false positives. The miR-TRAP method
seeks to avoid this issue by inclusion of a biotin tag on trans-
fected miRNA in an effort to select only for complexes containing
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specific miRNAs (Baigude et al., 2012). Perhaps most promising
of new technologies, crosslinking, ligation, and sequencing of
hybrids (CLASH) of RNA pulled down with AGO complexes,
may provide the ability to simultaneously discover mRNAs being
downregulated by RISC and the specific miRNA(s) which tar-
get them, as a miRNA sequence and a fragment of its targeted
RNA sequence will be ligated together and sequenced as a single
chimeric sequence (Helwak et al., 2013).
Although these immunoprecipitation-basedmethods can pro-
vide quantitative data about miRNA-target binding, their main
drawback is that they do not quantify the extent of mRNA
or protein downregulation. For this reason, a combination of
proteomic/transcriptomic profiing with the direct immunopre-
cipitation methods might offer the best quality datasets for
constructing miRNA-target interaction networks. A meta anal-
ysis of microarray data from miRNA transfection experiments
compared to Argonaute CLIP-Seq data not surprisingly showed
only partial overlap (Wen et al., 2011), presumably reflecting
the inherent biases of each method. Such discrepancies might
be predictive of direct versus indirect effects of miRNAs against
target mRNAs or proteins. Furthermore, investigation of the
dose-dependent effects of miRNAs against targets will likely be
important for appreciating how a miRNA or anti-miRNA thera-
peutic will behave in vivo, in particular whether or not there are
potentially beneficial or harmful dosage effects.
BUILDING AND VALIDATING NETWORKS
Functional screening of miRNA mimics generates a list of miR-
NAs that, when overexpressed, affect the desired phenotype to
varying degrees. In our experience, screening about 900 miRNAs
in a commercial mRNA mimic collection against a phenotypic
assay results in between 30 and 200 statistically significant hits,
(e.g., Colas et al., 2012), consistent with results from other com-
plex biological assays such as (Eulalio et al., 2012; Jentzsch et al.,
2012). The hits can be prioritized according to experimental goals
(e.g. filtered by expression within a target tissue). Once the targets
are identified through the strategies described above, they can be
mapped to the human PPI network. From the human PPI, a sub-
network is obtained by retaining the edges in which one of the
nodes is in the target list (Figure 3). This amounts to retaining all
the nodes in the PPI that directly interact with at least one target
gene. One can define rules about which nodes and edges from the
PPI should be included. For example, one may retain only those
edges in which both nodes are in the target list or those that are
functionally associated. This may result in a much more sparse
network.
How well do predicted networks reflect reality? A recent study
Becker et al. (2012) shows that miRs are encoded in the genome
as individual miRNA genes or as gene clusters and transcribed
as polycistronic units. These authors estimated that about 50%
of all miRNAs are co-expressed with neighboring miRNAs and,
most importantly, that these clusters coordinately regulate mul-
tiple members of protein-protein interaction network clusters.
Another study (Alshalalfa et al., 2012) showed that combin-
ing protein functional interaction networks with miR detection
revealed several miR-regulated interaction modules that were
indeed enriched in focal adhesion and prostate cancer pathways,
and yet another used screen data to reveal miRNA control of p53
(Becker et al., 2012). Illustrative of such recent efforts to deduce
high quality PPIs from miRNA screen datasets is the control of
epithelial to mesenchymal transition by miR-200 family (Sass
et al., 2011). The study first used an in silico approach compar-
ing miRNA target sites from published PAR-CLIP dataset (Hafner
et al., 2010) to proteomics datasets (Baek et al., 2008; Selbach
et al., 2008) to conclude that miRNAs have a propensity to target
proteins involved in multi-protein complexes. Furthermore, they
showed that protein complexes are coordinately regulated by clus-
ters of miRNAs, a conclusion supported by an analysis of miRNAs
that regulate transcription factor response elements in cell culture
(Becker et al., 2012). To probe the notion that miRNA clus-
ters coordinately control biological processes, Sass et al. (2011)
went on to show that additional members of the transcriptional
complex controlling E-cadherin, in addition to previously iden-
tified members, are under coordinate control by miRNAs that
reside within the miR141-200c cluster. Although these pioneering
studies support the idea that combining proteomics-based target
identification with a network-based strategy can be used to con-
struct reliable miRNA:protein interaction networks, it should be
emphasized that the validation has been sparse, and that large-
scale approaches, such as by siRNA screening, are needed to
evaluate the veracity of the regulatory networks.
SUMMARY AND PROSPECTS
Several features of miRNAs make functional, whole miRNAome
screening attractive as a platform to generate systems-level
descriptions of complex biological regulatory networks and help
interpret the massive transcriptome datasets emerging in all areas
of biology. First, the total number of miRNAs is relatively few
compared to siRNA or chemical libraries; yet, because of target
recognition degeneracy, the miRNAome regulates a large propor-
tion of the proteome. Second, sincemiRNA recognition of mRNA
transcripts is sequence based, the identification of mRNA tar-
gets poses fewer problems than associated with identification of
relevant targets of small molecules from chemical screens (Rix
and Superti-Furga, 2009), although methods for high through-
put identification of miRNA targets remain costly and far from
robust. Third, based on co-evolution of miRNAs and the net-
works they control, it is tempting to speculate that the nodes
targeted by the miRNAs might be selective for particular biolog-
ical processes, and hence comprise good points for therapeutic
intervention.
Currently, screening technology combined with the availabil-
ity of miRNA and si/shRNA libraries make it straightforward to
design and implement a moderate throughput whole genome
miRNAome or si/shRNA transcriptome screen (Figure 1). This
includes iPSC-based disease models, which offer an unprece-
dented ability to interrogate disease relevant processes and reveal
potential new drug targets. The bottleneck today is target identifi-
cation. Ideally, proteomics datasets should provide clear and con-
sistent results from over-expression of miRNAs. Unfortunately,
there is considerable variation between datasets obtained from
proteomics analysis of the same miRNA assayed by overexpres-
sion in the same cells. For instance, comparison of the pro-
teins downregulated by miR-34a (by Bargaje et al.) revealed
www.frontiersin.org August 2013 | Volume 4 | Article 223 | 7
Lemons et al. microRNAs and functional genomics
only 5 proteins in common out of 3365 (Bargaje et al., 2012)
and 1495 (Chen et al., 2011). Similarly, Shirdel et al. (Shirdel
et al., 2011) compared the results of miR-124 overexpression
and found only 10 common targets from 3 experiments, com-
prising only 3.7% of the smallest dataset. Similarly, the gen-
eral conclusion about computational prediction resources is that
none alone can perfectly identify mRNA targets, even when
mRNAs are filtered by analysis (e.g. microarray type) and cell
type (Baek et al., 2008; Selbach et al., 2008; Shirdel et al.,
2011). Nonetheless, our experience is consistent with the con-
clusion of Shirdel et al. that the current methods are suitable
to provide an initial prediction, and this is aided by recent
resources such as mirGator and mirDIP that integrate sev-
eral up-to-date miRNA target prediction databases. In practice,
PPI networks are often constructed from targets from multiple
prediction algorithms, see discussion in (Alexiou et al., 2009;
Shirdel et al., 2011). Furthermore, we use moderate through-
put siRNA screening against individual pathway components
FIGURE 3 | Pipeline for iterative process of network construction and
confirmatory screening of key nodes. The screen dataset (as in
Figure 1) is filtered and used for construction of the preliminary network.
We propose that it is beneficial to evaluate individual protein nodes by
screening specific si/shRNAs, pharmacological inhibitors or by protein
overexpression. Similarly, miR:protein interactions can be validated by
monitoring protein levels and direct interaction confirmed by site-directed
mutagenesis of the recognition elements in the mRNAs (see text). The
confirmatory cycles lead to a refined dataset and network. Statistical
significance of screen hits can be relaxed because of the confirmatory
process. The interactome shown contains miRNAs (yellow) found in a
screen to result in SERCA2 (ATP2A2) (green) inhibition >30%, p < 0.05,
are evolutionarily conserved, and are upregulated in human heart failure.
Inset: SERCA2 (node enlarged) centric network showing interaction with
miR92b and miR-142-3b that were determined by confirmatory screening
to target SERCA2 (unpublished data).
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to confirm the validity of predicted PPIs (Figure 3) (Colas et al.,
2012).
Finally, functional miRNA screening is a potentially powerful
method of identifying miRNAs and PPIs that control complex
biological processes. Although miRNA screening is mainly con-
sidered as a strategy to reveal miRNAs that naturally control
biological processes, we propose a more expanded view, and sug-
gest that miRNA screening also has the potential to interrogate
biological networks even if the active miRNAs are not natural reg-
ulators. Like chemical and si/shRNA functional genomics screens,
miRNAs screening, coupled to target identification and iterations
of PPI network construction, validation and refinement, might
offer an attractive pipeline to interrogate complex biology.
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